Quick Answer
Kairos Pharma, LTD. reported Shares Outstanding of 20.82 million shares for fiscal year 2025.
Kairos Pharma, LTD. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 20.82M | +51.6% |
| 2024 | 13.74M | +30.0% |
| 2023 | 10.56M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 20.82M | +62.1% | +17.3% |
| June 30, 2025 | 17.74M | — | +12.1% |
| March 31, 2025 | 15.83M | — | +15.2% |
| December 31, 2024 | 13.74M | +30.0% | +6.9% |
| September 30, 2024 | 12.85M | — | +21.6% |
| December 31, 2023 | 10.56M | — | — |
- Kairos Pharma, LTD. showed an increase of +51.6% in Shares Outstanding compared to the prior fiscal year.
- Over the 2023–2025 period, Kairos Pharma, LTD.’s shares outstanding has grown by 97.1% (from 10.56 million shares to 20.82 million shares).
- The most recent figure is from Kairos Pharma, LTD.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: